China Orders Whole‑Class Listing of "Orphine‑Type Substances" in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026
Policy / Regulatory

China Orders Whole‑Class Listing of “Orphine‑Type Substances” in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026

China's Ministry of Public Security (MPS), the National Health Commission (NHC), and the National Medical Products Administration (NMPA) jointly issued an announcement deciding to list the entire class of "orphine‑type…

BioMarin's Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World's Largest Rare Bone Disease Market
CompanyDrug

BioMarin’s Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World’s Largest Rare Bone Disease Market

Merck's KEYTRUDA (Pembrolizumab) Wins NMPA Approval in Early‑Stage High‑Risk TNBC – Label Expansion Beyond PD‑L1 CPS ≥ 20 for China's Only Approved PD‑1 Perioperative Breast Cancer Therapy
CompanyDrug

Merck’s KEYTRUDA (Pembrolizumab) Wins NMPA Approval in Early‑Stage High‑Risk TNBC – Label Expansion Beyond PD‑L1 CPS ≥ 20 for China’s Only Approved PD‑1 Perioperative Breast Cancer Therapy

Novo Nordisk's Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
CompanyDrug

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Novo Nordisk's Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China's Broadest‑Label Long‑Acting Growth Hormone
CompanyDrug

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

NMPA Approves Expanded Indication for Merck's Winrevair (Sotatercept) – First‑in‑Class Activin Signaling Inhibitor Now Covers WHO Functional Class II–IV PAH in China
CompanyDrug

NMPA Approves Expanded Indication for Merck’s Winrevair (Sotatercept) – First‑in‑Class Activin Signaling Inhibitor Now Covers WHO Functional Class II–IV PAH in China

China's CDE Slates Highlightll's Ginocitinib (TLL‑018) for Priority Review – First Domestic Dual‑Target JAK1/TYK2 Inhibitor for Rheumatoid Arthritis
CompanyDrug

China’s CDE Slates Highlightll’s Ginocitinib (TLL‑018) for Priority Review – First Domestic Dual‑Target JAK1/TYK2 Inhibitor for Rheumatoid Arthritis

Roche Reports Positive Phase III Interim Results for Sefaxersen in IgA Nephropathy – First mRNA‑Targeted Therapy Meets Primary Proteinuria Endpoint in IMAgINATION
CompanyDrug

Roche Reports Positive Phase III Interim Results for Sefaxersen in IgA Nephropathy – First mRNA‑Targeted Therapy Meets Primary Proteinuria Endpoint in IMAgINATION

European Commission Approves AbbVie's RINVOQ (Upadacitinib) for Juvenile Idiopathic Arthritis – Ninth EU Indication for the JAK Inhibitor
CompanyDrug

European Commission Approves AbbVie’s RINVOQ (Upadacitinib) for Juvenile Idiopathic Arthritis – Ninth EU Indication for the JAK Inhibitor

Roche Reports Positive Phase II Topline Data for Enicepatide – Once‑Weekly GLP‑1/GIP Agonist Cuts HbA1c by 2.65% and Body Weight by 15.5% at 48 Weeks
CompanyDrug

Roche Reports Positive Phase II Topline Data for Enicepatide – Once‑Weekly GLP‑1/GIP Agonist Cuts HbA1c by 2.65% and Body Weight by 15.5% at 48 Weeks

Biokin’s Bispecific ADC Izalontamab Bretecan Wins Eighth Breakthrough Therapy Designation in China – PD-1 Combo Targets First-Line PD-L1-Positive TNBC

Biokin's Bispecific ADC Izalontamab Bretecan Wins Eighth Breakthrough Therapy Designation in China – PD-1 Combo Targets First-Line PD-L1-Positive TNBC

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its self-developed first-in-class bispecific antibody–drug conjugate (ADC), Izalontamab Bretecan (BL-B01D1, "iza-bren"), in combination with a PD-1 monoclonal antibody (mAb), has been granted Breakthrough Therapy Designation (BTD) for the first-line treatment of…

HitGen Co‑Invests in Connexus Therapeutics' Series A – OrbiMed‑Backed Oncology Startup Founded on Phased Technology Licensing

HitGen Co‑Invests in Connexus Therapeutics’ Series A – OrbiMed‑Backed Oncology Startup Founded on Phased Technology Licensing

Company

Tigermed Posts 14% Revenue Growth in 2026 Interim Results – China’s No.1 Clinical CRO Sees Bookings Rebound While Fair‑Value Losses Swing Reported Profit Negative

Rainmed Medical Reports 41% Revenue Growth in 2026 Interim Results – caFFR Consumables Drive Gross Margin to 63.2% as Losses Narrow 31%
Company

Rainmed Medical Reports 41% Revenue Growth in 2026 Interim Results – caFFR Consumables Drive Gross Margin to 63.2% as Losses Narrow 31%

InnoCare Strikes Strategic Research and Licensing Deal With Eli Lilly – Up to USD 100 Million Upfront and USD 3.25 Billion in Milestones for Up to Five Innovative Target Programs
CompanyDeals

InnoCare Strikes Strategic Research and Licensing Deal With Eli Lilly – Up to USD 100 Million Upfront and USD 3.25 Billion in Milestones for Up to Five Innovative Target Programs

Sanyou Bio and NovoCodex Forge Strategic ADC Partnership – AI‑Driven Antibody Discovery Meets Site‑Specific Conjugation for Dual‑Targeting, Dual‑Payload Programs
CompanyDeals

Sanyou Bio and NovoCodex Forge Strategic ADC Partnership – AI‑Driven Antibody Discovery Meets Site‑Specific Conjugation for Dual‑Targeting, Dual‑Payload Programs

Shanghai RAAS to Acquire 100% of Boehringer Ingelheim China Investment Entity for Up to RMB 20 Million – Deal Secures End‑to‑End In‑House Control of First‑in‑Class SR604 Injection
CompanyDeals

Shanghai RAAS to Acquire 100% of Boehringer Ingelheim China Investment Entity for Up to RMB 20 Million – Deal Secures End‑to‑End In‑House Control of First‑in‑Class SR604 Injection

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
M&A and Licensing
Sunflower Pharmaceutical to Acquire 100% of Dongxu Pharmaceutical for RMB 780,000 – Deal Targets Multi‑Line Marketing Network Efficiency
CompanyDeals

Sunflower Pharmaceutical to Acquire 100% of Dongxu Pharmaceutical for RMB 780,000 – Deal Targets Multi‑Line Marketing Network Efficiency

Sunflower Pharmaceutical Co., Ltd. (SHE: 002737) announced it will acquire a 100% equity stake in Dongxu Pharmaceutical for a total consideration of RMB 780,000, a transaction intended to promote multi‑line,…

Henlius Secures Global Exclusive License Deal With Amberstone Biosciences – Conditionally Activated TCEs for Solid Tumors Built on the pH‑Sensitive T‑MATE Platform
CompanyDeals

Henlius Secures Global Exclusive License Deal With Amberstone Biosciences – Conditionally Activated TCEs for Solid Tumors Built on the pH‑Sensitive T‑MATE Platform

Tangzhi Pharma Secures Nearly RMB 100 Million Exclusive Financing from Fengnian Capital – Glyco Raw‑Material Platform Targets ADC and Nucleic‑Acid Drug Boom
CompanyDeals

Tangzhi Pharma Secures Nearly RMB 100 Million Exclusive Financing from Fengnian Capital – Glyco Raw‑Material Platform Targets ADC and Nucleic‑Acid Drug Boom

BoomRay Licenses Preclinical Radioligand Therapy to Novartis in Exclusive Global Deal Worth Up to USD 900 Million – China RDC Specialist Adds Big Pharma Validation
CompanyDeals

BoomRay Licenses Preclinical Radioligand Therapy to Novartis in Exclusive Global Deal Worth Up to USD 900 Million – China RDC Specialist Adds Big Pharma Validation

Shanghai Shenqi Medical Partners with Bio-heart to Commercialize BioHeart Bioresorbable Sirolimus‑Eluting Coronary Stent – Ultra‑Thin 90μm Strut Design Targets Deliverability and Radial Strength
CompanyDeals

Shanghai Shenqi Medical Partners with Bio-heart to Commercialize BioHeart Bioresorbable Sirolimus‑Eluting Coronary Stent – Ultra‑Thin 90μm Strut Design Targets Deliverability and Radial Strength

- Advertisement -
Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027
CompanyDeals

Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World's First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development
CompanyDeals

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World’s First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development

Qiantang Longyue Closes Over RMB 100 Million A++ Round Led by Huimei Capital – Drug Delivery Systems Platform Nears Unicorn Status
CompanyDeals

Qiantang Longyue Closes Over RMB 100 Million A++ Round Led by Huimei Capital – Drug Delivery Systems Platform Nears Unicorn Status

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
CompanyDeals

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented
Policy / Regulatory

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

China's National Medical Products Administration (NMPA) released the 109th Catalog of Reference Listed Drugs for Chemical Generic Drugs, adding 30 new product specifications and supplementing information for 24 product specifications…

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening
Policy / Regulatory

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

China's NHC Issues Landmark Rare‑Disease Notice – Mandating Province‑Wide Clinics and Quality Control Networks by End‑2026
Policy / Regulatory

China’s NHC Issues Landmark Rare‑Disease Notice – Mandating Province‑Wide Clinics and Quality Control Networks by End‑2026

MIIT and Nine Departments Issue China's "15th Five‑Year Plan for Pharmaceutical Industry Development" – Innovative Drug Sector Targeted to Grow Over 20 % Annually Through 2030
Policy / Regulatory

MIIT and Nine Departments Issue China’s “15th Five‑Year Plan for Pharmaceutical Industry Development” – Innovative Drug Sector Targeted to Grow Over 20 % Annually Through 2030

More News

Novo Nordisk Says 1.5 Million Patients Are Now on the Oral Wegovy Pill – Capacity to Expand 10‑Fold by 2030 as Sales Growth Outpaces Eli Lilly's Foundayo
Company

Novo Nordisk Says 1.5 Million Patients Are Now on the Oral Wegovy Pill – Capacity to Expand 10‑Fold by 2030 as Sales Growth Outpaces Eli Lilly’s Foundayo

Novo Nordisk Completes Restructuring With Over DKK 10 Billion in Cost Savings – Semaglutide Growth Pressure Drives Pivot Toward CagriSema and a Five‑Blockbuster Pipeline
Company

Novo Nordisk Completes Restructuring With Over DKK 10 Billion in Cost Savings – Semaglutide Growth Pressure Drives Pivot Toward CagriSema and a Five‑Blockbuster Pipeline

Jenscare's JensClip Wins NMPA Registration Approval – Self‑Locking Transcatheter Mitral Valve Repair Clip Enters the Chinese Market
CompanyMedical Device

Jenscare’s JensClip Wins NMPA Registration Approval – Self‑Locking Transcatheter Mitral Valve Repair Clip Enters the Chinese Market

BMS Plans 265 Princeton Layoffs – Bristol Myers Squibb Extends Its USD 2 Billion Cost Cutting Drive
Company

BMS Plans 265 Princeton Layoffs – Bristol-Myers Squibb Extends Its USD 2 Billion Cost Cutting Drive

Allist Pharmaceuticals' NDA Accepted by China's CDE for Furmonertinib in Adjuvant NSCLC – Third‑Generation EGFR‑TKI Targets Post‑Resection Patients with Exon 19 Deletion or L858R Mutations
CompanyDrug

Allist Pharmaceuticals’ NDA Accepted by China’s CDE for Furmonertinib in Adjuvant NSCLC – Third‑Generation EGFR‑TKI Targets Post‑Resection Patients with Exon 19 Deletion or L858R Mutations

Merck's Subcutaneous Pembrolizumab KEYJECT Wins MHLW Approval Across All KEYTRUDA Indications in Japan – Phase III Shows Comparable Exposure and 45% ORR in First-Line Metastatic NSCLC
CompanyDrug

Merck’s Subcutaneous Pembrolizumab KEYJECT Wins MHLW Approval Across All KEYTRUDA Indications in Japan – Phase III Shows Comparable Exposure and 45% ORR in First-Line Metastatic NSCLC

Roche's Susvimo Wins European Commission Approval for nAMD – Refillable Ranibizumab Implant Delivers Vision Outcomes Equivalent to Monthly Injections with Just Two Refills Per Year
CompanyDrug

Roche’s Susvimo Wins European Commission Approval for nAMD – Refillable Ranibizumab Implant Delivers Vision Outcomes Equivalent to Monthly Injections with Just Two Refills Per Year

Grünenthal to Acquire Bayer's Stivarga (Regorafenib) for Up to €375 Million – Oral Multikinase Oncology Franchise Changes Hands Ahead of 2029–2030 Loss of Exclusivity
Others

Grünenthal to Acquire Bayer’s Stivarga (Regorafenib) for Up to €375 Million – Oral Multikinase Oncology Franchise Changes Hands Ahead of 2029–2030 Loss of Exclusivity

Show More